Astrazeneca Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the next five years. The world's largest vaccine maker, based in Pune, currently has the capacity to produce 3 billion doses annually but only sells about half of that. CEO Adar Poonawalla is optimistic about the increasing uptake of vaccines globally as countries boost their healthcare budgets.

/PRNewswire/ -- The global over-the-counter (OTC) analgesics market size is estimated to grow by USD 7.20 billion from 2024-2028, according to Technavio. The...

/PRNewswire/ -- The global protein therapeutics market size is estimated to grow by USD 172.8 billion from 2024-2028, according to Technavio. The market is...

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi